Investing.com - Regeneron Pharma (NASDAQ:REGN) reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $25.8 on revenue of $5.14B. Analysts polled by Investing.com anticipated EPS of $17.91 on revenue of $3.97B.
Regeneron Pharma shares are up 20.25% from the beginning of the year, still down 11.61% from its 52 week high of $657.24 set on August 5, 2020. They are outperforming the S&P 500 which is up 17.22% from the start of the year.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar